Literature DB >> 8462156

Cardiotoxicity of human recombinant interleukin-2 in rats. A morphological study.

J Zhang1, Z X Yu, S L Hilbert, M Yamaguchi, D P Chadwick, E H Herman, V J Ferrans.   

Abstract

BACKGROUND: One of the side effects of interleukin 2 (IL-2) cancer immunotherapy in humans is the vascular leak syndrome, which is frequently associated with depression of myocardial function, myocarditis, and myocardial necrosis. METHODS AND
RESULTS: To investigate this cardiotoxicity, IL-2 (three doses of 5 x 10(5) Cetus units/day i.p.) was given to rats for 2, 3, or 5 days. Heart, lung, liver, spleen, and kidney tissues were studied by light and electron microscopy and with immunoperoxidase techniques. Cardiac changes consisted of focal lymphocytic and eosinophilic infiltration, myocyte vacuolization, myofibrillar loss, and necrosis. Ultrastructural alterations included swelling of endothelial cells, with dissociation of intercellular junctions, migration of lymphocytes into the interstitium, and interstitial hemorrhage and edema. Close contact between infiltrating lymphocytes, particularly large granular lymphocytes, and cardiac myocytes was often observed in areas of tissue damage. All lesions were more severe on day 5 than on days 2 and 3. Immunoperoxidase stains demonstrated asialo GM1 ganglioside antibody-positive, granular lymphocytes to be much more frequent in myocardium of IL-2-treated rats than in that of control rats.
CONCLUSIONS: Although we cannot exclude the possibility of a direct toxic effect of IL-2 on myocytes, our observations suggest that the myocardial damage produced by this agent is triggered by IL-2-activated lymphocytes that exert cytolytic effects, first on endothelial cells and then on cardiac myocytes, thus producing lesions that involve both the cardiac microcirculation and the muscle cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8462156     DOI: 10.1161/01.cir.87.4.1340

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  11 in total

1.  Fulminant myocarditis owing to high-dose interleukin-2 therapy for metastatic melanoma.

Authors:  P Thavendiranathan; D Verhaert; K L Kendra; S V Raman
Journal:  Br J Radiol       Date:  2011-05       Impact factor: 3.039

Review 2.  Cancer Treatment-Associated Pericardial Disease: Epidemiology, Clinical Presentation, Diagnosis, and Management.

Authors:  Chandra K Ala; Allan L Klein; Javid J Moslehi
Journal:  Curr Cardiol Rep       Date:  2019-11-25       Impact factor: 2.931

Review 3.  Heart failure induced by non-cardiac drugs.

Authors:  Lars Slørdal; Olav Spigset
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 4.  Cardiovascular Toxicities Associated with Cancer Immunotherapies.

Authors:  Daniel Y Wang; Gosife Donald Okoye; Thomas G Neilan; Douglas B Johnson; Javid J Moslehi
Journal:  Curr Cardiol Rep       Date:  2017-03       Impact factor: 2.931

5.  Acute and Chronic Cardiopulmonary Effects of High Dose Interleukin-2 Therapy: An Observational Magnetic Resonance Imaging Study.

Authors:  Jakub Lagan; Josephine H Naish; Christien Fortune; Christopher Campbell; Shien Chow; Manon Pillai; Joshua Bradley; Lenin Francis; David Clark; Anita Macnab; Gaetano Nucifora; Rebecca Dobson; Erik B Schelbert; Matthias Schmitt; Robert Hawkins; Christopher A Miller
Journal:  Diagnostics (Basel)       Date:  2022-05-30

6.  Myocardial changes in acute Trypanosoma cruzi infection. Ultrastructural evidence of immune damage and the role of microangiopathy.

Authors:  Z A Andrade; S G Andrade; R Correa; M Sadigursky; V J Ferrans
Journal:  Am J Pathol       Date:  1994-06       Impact factor: 4.307

Review 7.  Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer.

Authors:  Ruth Whittington; Diana Faulds
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

Review 8.  Myocardial remodeling in viral heart disease: possible interactions between inflammatory mediators and MMP-TIMP system.

Authors:  Matthias Pauschinger; Kumaran Chandrasekharan; Heinz-Peter Schultheiss
Journal:  Heart Fail Rev       Date:  2004-01       Impact factor: 4.214

9.  Onset and progression of pathological lesions in transforming growth factor-beta 1-deficient mice.

Authors:  G P Boivin; B A O'Toole; I E Orsmby; R J Diebold; M J Eis; T Doetschman; A B Kier
Journal:  Am J Pathol       Date:  1995-01       Impact factor: 4.307

10.  Experimental rat model representing both acute and chronic heart failure related to autoimmune myocarditis.

Authors:  S Koyama; M Kodama; T Izumi; A Shibata
Journal:  Cardiovasc Drugs Ther       Date:  1995-10       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.